)
Pay in 4 interest-free payments of $6.84 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
& Vlatkovic, I
Side effects are typically minimal but can include temporary soreness at the injection site
Retatrutide's Phase 2 data (up to 24.2%) suggests superior efficacy compared to both single and dual agonists, potentially offering clinical advantage for patients seeking maximal weight loss
As such, including an additional outcome with less clinically meaningful threshold would overload the study results with redundant information rather than providing added clinical insights
Table 2 Baseline characteristics of CVOTs involving GLP-1 receptor agonists and key findings
US$ 27.90
US$ 27.35
US$ 21.91
